Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16959228 | 0.79 | IMPDH2 (0.38) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL16950833 | 0.74 | SOS1 (0.37) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL13715533 | 0.74 | IMPDH2 (0.41) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL16956153 | 0.72 | SOS1 (0.35) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL23563601 | 0.72 | POLB (0.38) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL18145874 | 0.72 | AR (0.40) | MAPT | |
| SCHEMBL30013247 | 0.71 | CYP1A2 (0.38) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL23525874 | 0.71 | CYP1A2 (0.38) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL29945799 | 0.71 | CYP1A2 (0.38) | IMPDH2IMPDH1SOS1POLBGAA | |
| SCHEMBL23525875 | 0.71 | CYP1A2 (0.38) | IMPDH2IMPDH1SOS1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273238-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-08-02 | — | — | US | disclosed |
| US-9879016-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | IMPDH2 185/4885IMPDH1 139/4885SOS1 2930/4885 |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | IMPDH2 185/4885IMPDH1 139/4885SOS1 2930/4885 |
| US-10273238-B2 | Indazolones as modulators of TNF signaling | TNF, TNFRSF9, TNFRSF1A | IMPDH2 185/4885IMPDH1 139/4885SOS1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.